At the American Diabetes Association's 2026 Scientific Sessions in New Orleans, researchers presented findings that could reshape how doctors care for a particularly vulnerable group: adults living with both obesity and autoimmune disease. The discovery, drawn from electronic health records of more than 26,000 Florida patients, shows that GLP-1RA medications—commonly prescribed for weight loss and blood sugar control—dramatically reduce the risk of serious cardiac events in this high-risk population.
The significance of this research lies in addressing a gap that has long troubled clinicians. Obesity and autoimmune disease each independently increase the risk of cardiovascular complications and blood clots. When someone has both conditions, that risk multiplies. Yet until now, there was scant evidence to guide treatment decisions for these patients. "This is a high-risk population, and historically we've had limited data to guide treatment decisions," said Dr. Amy Sheer, an associate professor of medicine and director of the Obesity Medicine Fellowship program at the University of Florida.
The study analyzed data from the OneFlorida+ network spanning 2014 to 2024, comparing cardiac outcomes between patients taking GLP-1RA medications and those who did not. The results were striking. Patients on GLP-1RA showed a 44% decreased risk of death—a finding that drew particular attention from outside experts. They experienced a 31% lower risk of pulmonary embolism, a 17% reduction in venous thromboembolism, and a 21% decrease in emergency department visits. Even modest benefits appeared for stroke risk, which decreased by 13%.
What makes these numbers remarkable is their real-world context. These weren't patients in a tightly controlled clinical trial; they were Florida residents receiving routine care through standard medical networks. The consistency of benefits across multiple serious outcomes suggests something fundamental may be happening at the biological level when GLP-1RA therapy is combined with treatment for autoimmune disease.
The research is the first to examine GLP-1RA effects specifically in patients with both obesity and varied autoimmune conditions—gastrointestinal disorders like celiac disease, skin conditions like vitiligo, endocrine diseases like Type 1 diabetes, and musculoskeletal diseases like rheumatoid arthritis. This breadth matters because it suggests the protective effect isn't limited to a single autoimmune diagnosis.
Dr. Sheer emphasized the clinical implications. "In this real-world analysis, we found a consistent signal toward fewer serious complications, including blood clots, and lower mortality among patients treated with GLP-1RA," she said. The findings may encourage what she calls "a more thoughtful, individualized approach" to prescribing these therapies in higher-risk patients.
Dr. Fatima Cody Stanford, an obesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School who was not involved in the research, underscored its significance: "The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention." Stanford noted that the benefits appear to extend far beyond the medications' known effects on weight and blood sugar, potentially "fundamentally alter[ing] the disease trajectory for some of our highest-risk patients."
For people managing both conditions, the message is hopeful. Medications already prescribed to address their autoimmune disease or weight challenges may carry an additional, life-protective benefit they didn't know existed.